Singapore, Aug. 19 -- The Health Sciences Authority (HSA) has approved Sanofi and AstraZeneca's BEYFORTUS (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.BEYFORTUS (nirsevimab) is the first immunisation designed for first RSV season, including for those born healthy at term or preterm, or with specific health conditions.

Globally, around 2 in 3 babies will catch RSV before their first birthday and it remains the most common cause of lower respiratory tract disease, including bronchiolitis and pneumoni...